Lao version of Apelvis user manual

Apelvis (trade name: Piqray), as an innovative phosphatidylinositol-3kinase (PI3K) alpha inhibitor, has demonstrated excellent efficacy in the treatment of malignant tumors. Especially for patients with advanced or metastatic breast cancer who carry PIK3CA gene mutations that are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-). It has become one of the important treatment options. Although the original drug is produced by Novartis, pharmaceutical companies such as Lucius in Laos have also successfully launched generic versions of it, bringing new hope for treatment to more patients. Below is a usage guide for the Lao version of Apelvis, designed to teach patients how to use the drug safely and effectively.

1. Indications and preparation before use

The Lao version of Apelvis is mainly suitable for patients with HR+/HER2- advanced or metastatic breast cancer whose disease has progressed after endocrine therapy and who are confirmed to carry PIK3CA gene mutations. Before using this drug, patients should undergo a comprehensive physical examination, including liver and kidney function, blood routine, etc., to ensure that their physical condition is suitable for treatment with this drug. At the same time, patients need to inform their doctors about all medications they are taking to avoid potential drug interactions.

2. Correct usage and dosage

The Lao version of Apelvis is usually in the form of tablets, and the specific dosage and medication regimen must strictly follow the doctor's prescription. Generally speaking, the recommended dose is 300 mg once daily (two tablets of 150 mg), and it is recommended to take it with a meal to improve drug absorption. Patients should try to take the medication at the same time each day and keep the tablets swallowed whole and avoid chewing, crushing or splitting the tablets. If you occasionally miss a dose, you can take it as soon as you remember. However, if it is close to the time of the next dose, you should skip the dose and continue taking the medicine as originally planned.

2. Important matters needing attention

1. Monitor adverse reactions: During the use of Apelvis, patients may encounter adverse reactions such as diarrhea, nausea, vomiting, rash, fatigue, etc. In the event of severe discomfort, seek medical advice immediately and inform your doctor that you are taking Apelvis.

2. Diet adjustment: Patients are advised to keep a light diet and avoid greasy or spicy foods to reduce gastrointestinal discomfort. Also, ensure adequate fluid intake.

3. Regular follow-up: Patients should return to the hospital for regular follow-up as required by the doctor so that the doctor can monitor changes in condition and drug efficacy and adjust the treatment plan in a timely manner.

4. Contraception and fertility: Apelvis may cause harm to the fetus. Therefore, patients should take effective contraceptive measures to avoid pregnancy during treatment and for a period of time after stopping the drug. For young patients who have fertility needs, they should be fully discussed with their doctor before treatment.

4. Be cautious about drug interactions

Apelix may interact with other medications, affecting their effectiveness or increasing the risk of side effects. Therefore, before using the Lao version of Apelvis, patients must inform their doctors in detail about all the drugs they are taking, including prescription drugs, over-the-counter drugs, Chinese herbal medicines, etc. The doctor will adjust the medication plan according to the patient's specific situation to ensure the safety and effectiveness of the treatment.

In summary, the Lao version of Apelvis provides a new treatment option for patients with advanced or metastatic breast cancer carrying PIK3CA gene mutations. However, in order to use this drug safely and effectively, patients need to strictly follow the doctor's instructions, take the medicine on time and in the right amount, and pay close attention to their own condition. At the same time, maintaining good communication with doctors and providing timely feedback on problems and discomforts during treatment are crucial to ensuring treatment effects and patient safety.